Postmarketing Surveillance Study of Atrovent® in Chronic... | NCT02236715

Studies
Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

NCT02236715

Sponsor

Boehringer Ingelheim

Status

Completed

Last Update Posted

Sep 11, 2014Estimated

Enrollment

1,039Actual

Phase

Not provided

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Atrovent®

Countries

Not provided

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Sep 2014

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Sep 1999

Primary Completion Date

Feb 2000Actual

Completion Date

Not provided

First Submitted Date

Sep 10, 2014

First Submission Date that Met QC Criteria

Sep 10, 2014

First Posted Date

Sep 11, 2014Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Sep 10, 2014

Last Update Posted Date

Sep 11, 2014Estimated

Description Module

Brief Summary

Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

1,039Actual

Label	Type	Description	Intervention Names
Chronic Obstructive Airways Disease			Drug: Atrovent®

Name	Type	Description	Arm Group Labels	Other Names
Atrovent®	Drug		Chronic Obstructive Airways Disease

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Change in total severity of the clinical picture rated on a 4-point scale		after 4 weeks

Secondary Outcomes

Measure	Description	Time Frame
Assessment of efficacy by investigator on a 4-point scale		after 4 weeks
Assessment of efficacy by patient on a 4-point scale		after 4 weeks
Assessment of tolerability by investigator on a 4-point scale

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease
Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion Criteria:

Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

30 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Patients with chronic obstructive airways disease recruited at general practitioners, pneumologists, internists

Sampling Method

Non-Probability Sample

Condition Browse Module

MeSH Terms

ID	Term
D029424	Pulmonary Disease, Chronic Obstructive

Ancestor Terms

ID	Term
D008173	Lung Diseases, Obstructive
D008171	Lung Diseases
D012140	Respiratory Tract Diseases
D002908	Chronic Disease

Browse Leaves

Not provided

Browse Branches

Not provided

Intervention Browse Module

MeSH Terms

ID	Term
D009241	Ipratropium

Ancestor Terms

ID	Term
D001286	Atropine Derivatives
D014326	Tropanes
D053961	Azabicyclo Compounds
D001372	Aza Compounds

Browse Leaves

Not provided

Browse Branches

Not provided